Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
Werte in diesem Artikel
Machine-learning techniques keep improving efficiency in one industry after another. One corner of the economy where investors expect another big leap forward is the world of drug development.For every commercial-stage drug out there that generates millions and sometimes billions in annual sales, there were thousands of new drug candidates that didn't get across the finish line. You don't need a life-science background to see an opportunity to streamline this process with help from artificial intelligence (AI) and new automation techniques.Recursion Pharmaceuticals (NASDAQ: RXRX) has gained a lot of attention in recent years with an AI-powered drug-discovery platform that aims to reduce the amount of trial and error that's required to discover successful new drug candidates.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Ausgewählte Hebelprodukte auf Recursion Pharmaceuticals, A
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Recursion Pharmaceuticals, A
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: MotleyFool
Nachrichten zu Recursion Pharmaceuticals, Inc Registered Shs -A-
Analysen zu Recursion Pharmaceuticals, Inc Registered Shs -A-
Keine Analysen gefunden.